구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | anti-CD19/CD22 CAR-T cells (anti-CD19/CD22 CAR-T cells) Nanjing IASO Biotechnology Co., Lt…·CD19 28 trials |
|---|---|
Overview Program | anti-CD19/CD22 CAR-T cells |
Overview Company | Nanjing IASO Biotechnology Co., Ltd. |
Overview Modality | CGT |
Overview Target | CD19 |
Overview Indication | MRD-positive; Acute Lymphoblastic Leukemia |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Tandem CD19/CD22 CAR T-cells as potential therapy for children and young adults with high-risk r/r B-ALL.. Chimeric antigen receptor (CAR) T-cells targeting CD19 have shown impressive outcomes in refractory/relapsed B-cell acute lymphoblastic leukaemia (r/r B-ALL); however, frequent relapse demands multi-targeted approaches. We report Spanish clinical data on the safety and efficacy of tandem anti… |
Toxicology CRS | Reported |
Clinical Safety signal | Tandem CD19/CD22 CAR T-cells as potential therapy for children and young adults with high-risk r/r B-ALL.. Chimeric antigen receptor (CAR) T-cells targeting CD19 have shown impressive outcomes in refractory/relapsed B-cell acute lymphoblastic leukaemia (r/r B-ALL); however, frequent relapse demands multi-targeted approaches. We report Spanish clinical data on the safety and efficacy of tandem anti… |
Clinical Selected reported efficacy | ORR 1% |
Clinical Reported ORR | 1% |
Clinical Result source | ClinicalTrials.gov NCT03287817 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT03287817 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | anti-CD19/CD22 CAR-T cells (anti-CD19/CD22 CAR-T cells) Nanjing IASO Biotechnology Co., Lt…·CD19 28 trials |
|---|---|
Overview Program | anti-CD19/CD22 CAR-T cells |
Overview Company | Nanjing IASO Biotechnology Co., Ltd. |
Overview Modality | CGT |
Overview Target | CD19 |
Overview Indication | MRD-positive; Acute Lymphoblastic Leukemia |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Tandem CD19/CD22 CAR T-cells as potential therapy for children and young adults with high-risk r/r B-ALL.. Chimeric antigen receptor (CAR) T-cells targeting CD19 have shown impressive outcomes in refractory/relapsed B-cell acute lymphoblastic leukaemia (r/r B-ALL); however, frequent relapse demands multi-targeted approaches. We report Spanish clinical data on the safety and efficacy of tandem anti… |
Toxicology CRS | Reported |
Clinical Safety signal | Tandem CD19/CD22 CAR T-cells as potential therapy for children and young adults with high-risk r/r B-ALL.. Chimeric antigen receptor (CAR) T-cells targeting CD19 have shown impressive outcomes in refractory/relapsed B-cell acute lymphoblastic leukaemia (r/r B-ALL); however, frequent relapse demands multi-targeted approaches. We report Spanish clinical data on the safety and efficacy of tandem anti… |
Clinical Selected reported efficacy | ORR 1% |
Clinical Reported ORR | 1% |
Clinical Result source | ClinicalTrials.gov NCT03287817 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT03287817 |
추천 비교
추천 비교